• 1
    Peterson LC, Rao KV, Crosson JT, White JG. Fechtner syndrome: a variant of Alport's syndrome with leukocyte inclusions and macrothrombocytopenia. Blood 1985;65:397406.
  • 2
    Alport AC. Hereditary familial congenital hemorrhagic nephritis. Br J Med 1927;1:504506.
  • 3
    Epstein CJ, Shaud MA, Piel CF, et al. Hereditary macrothrombocytopenia, nephritis and deafness. Am J Med 1972;52:299310.
  • 4
    Greinacher A, Nieuwenhuis HK, White JC. Sebastian platelet syndrome: a new variant of hereditary macrothrombocytopenia with leukocyte inclusions. Blut 1990;61:282288.
  • 5
    May R. Leukocyteneinschlusse. Deutsch Arch Klin Med 1909;96:16.
  • 6
    Hegglin R. Gleichzeitige konstitutionelle Veranderungen an Neutrophilen und Thrombozyten. Helv Med Acta 1945;12:439440.
  • 7
    Toren A, Amariglio N, Rozenfeld-Granot G, et al. Genetic linkage of autosomal-dominant Alport syndrome with leukocyte inlusions and macrothrombocytopenia (Fechtner syndrome) to chromosome 22q11–13. Am J Hum Genet 1999;65:17111717.
  • 8
    Toren A, Rozenfeld-Granot G, Rocca B, et al. Autosomal-dominant giant platelet syndromes: a hint of the same genetic defect as in Fechtner syndrome owing to a similar genetic linkage to chromosome 22q11–13. Blood 2000;96:34473451.
  • 9
    Martignetti JA, Heath KE, Harris J, et al. The May-Hegglin anomaly (MHA) gene localizes to a <1Mb region on chromosome 22q12.3–13.1. Am J Hum Genet 2000;66:14491454.
  • 10
    Cusano R, Gangarossa S, Forabosco P, et al. Localization of the gene responsible for FTNS in a region<600 kb on 22q11-q13. Eur J Hum Genet 2000;8:895899.
  • 11
    Kunishima S, Kojima T, Tanaka T, et al. Mapping of a gene for MHA to chromosome 22q. Hum Genet 1999;105:379383.
  • 12
    May Hegglin/FTNS Consortium. Group 1: Seri M, Cusano R, Gangarossa S, et al.; Group 2: Savino M, Del Vecchio M, d'Apolito M, et al.; Group 3: Balduini CL, Noris P, Magrini U, Belletti S; Group 4: Heath KE, Babcock M, Glucksman M, et al. Mutations in MYH9 result in May-Hegglin anomaly, Fechtner and Sebastian syndrome. Nat Genet 2000;26:103105.
  • 13
    Kelley MJ, Jawien W, Ortel TL, Korczak JF. Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. Nat Genet 2000;26:108109.
  • 14
    Heath KE, Campos-Barros A, Toren A, et al. Nonmuscle myosin heavy chain 9 gene (MYH9) mutations define a spectrum of autosomal-dominant macrothrombocytopenias: May-Hegglin anomaly, Fechtner, Sebastian, Epstein and Alport like syndromes. Am J Hum Genet 2001;69:10331045.
  • 15
    Argraves WS, Dickerson K, Burgess WH, Ruoslahti E. Fibulin-1, a novel protein that interacts with the fibronectin receptor beta subunit cytoplasmic domain. Cell 1989;58:623629.
  • 16
    Roark EF, Keene DR, Haudenschid CC, Godyna S, Little CD, Argraves WS. The association of human fibulin-1 with elastic fibers: an immunohistological, ultrastructural, and RNA study. J Histochem Cytochem 1995;43:401411.
  • 17
    Pan TC, Kosta G, Zhang RZ, Timpl R, Chu ML. Complete exon-intron organization of the mouse fibulin-1–1 gene and its comparison with the human fibulin-1–1 gene. FEBS Lett 1999;444:3842.
  • 18
    Gershoni-Baruch R, Baruch Y, Viener A, Lichtig C. FTNS: clinical and genetic aspects. Am J Med Genet 1988;31:357367.
  • 19
    Rocca B, Laghi F, Zini G, Maggiano N, Landolfi R. Fechtner syndrome: report of a third family and literature review. Br J Hematol 1993;85:423426.
  • 20
    Bizzaro N. L'anomalia di May-Hegglin: una rara causa di piastrinopenia congenita. Descrizione della malattia e di un vasto gruppo familiare del Veneto orientale. Med Lab 1997;5:165171.
  • 21
    Moxey-Mims MM, Young G, Silverman A, Selby DM, White JG, Kher KK. End-stage renal disease in two pediatric patients with Fechtner syndrome. Pediatr Nephrol 1999;13:782786.
  • 22
    Dunham I, Shimizu N, Roe BA, et al. The DNA sequence of chromosome 22. Nature 1999;402:489495.
  • 23
    Spear GS, Slusser RJ. Alport's syndrome: emphasizing electron microscopic studies of the glomerulus. Am J Pathol 1972;69:213222.
  • 24
    Yelin R, Dahary D, Sorek R, et al. Widespread occurrence of antisense transcription in the human genome. Nat Biotechnol 2003;21:379386.
  • 25
    Sharp PA. RNA interference. Genes Dev 2001;15:485490.
  • 26
    Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000;101:2533.
  • 27
    Blin-Wakkach C, Lezot F, Ghoul-Mazgar S, et al. Endogenous Msx1 antisense transcript: in vivo and in vitro evidences, structure, and potential involvement in skeleton development in mammals. Proc Natl Acad Sci USA 2001;98:73367341.
  • 28
    Malik KT, Wallace JI, Ivins SM, Brown KW. Identification of an antisense WT1 promoter in intron 1: implications for WT1 gene regulation. Oncogene 1995;1:15891595.